Key Takeaway
GHK-Cu has topical research behind it; the selected sources do not establish injectable side-effect rates in women. Side effects women report from injections (redness at the site, nausea, flushing, lightheadedness, headache) are anecdotal, and as of September 2026 injectable GHK-Cu sits in no FDA compounding category.
What is known about GHK-Cu side effects in women comes from two very different bodies of evidence. The 2018 review by Pickart and Margolina summarizes topical cosmetic work. The completed topical trial and current registry entry compared below answer narrower, source-specific questions; neither measures injectable side-effect rates in women. The effects women report after injections, such as redness at the injection site, nausea, lightheadedness and flushing, are user reports, not measured incidences. Being a peptide the body makes does not by itself establish that injecting it is safe. Correction, September 2026: an earlier version of this page presented these effects as generally mild and uncommon under physician supervision; no source supports either the frequency or the supervision framing, and the wording has been revised.
What a completed topical study and a registry entry tell us
| Source | Design and route | Observed finding or study plan | What it answers about women |
|---|---|---|---|
| Miller et al., 2006 | Randomized post-laser skin-care regimens with or without topical GHK-Cu; 13 patients completed the study. | No significant between-group difference in objective erythema resolution, wrinkles or skin quality. A patient questionnaire favored the GHK-Cu regimen for skin quality (P=.04). | The abstract does not give a women-specific adverse-event table or injectable outcomes. |
| NCT07437586 | Planned split-wound comparison of 0.1% topical GHK-Cu gel against vehicle; estimated enrollment 60. | The registry describes a wound-healing study. No results were posted in the record checked October 3, 2026. | A protocol cannot supply observed symptom rates, and a topical intervention cannot establish injection-specific rates. |
These sources answer different questions. The completed study separates objective skin measures from subjective patient ratings; the registry describes intended measurements. Neither provides a numerical probability for nausea, flushing or headache after injections in women. Keeping the route, participant group and endpoint together avoids turning a topical result into an injectable side-effect claim.
How GHK-Cu and Women's Health
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a copper-binding peptide found naturally in human plasma, saliva, and urine. It plays a role in wound healing, collagen synthesis, and anti-inflammatory signaling. Plasma GHK declines with age, from about 200 ng/mL at age 20 to about 80 ng/mL at 60 (Pickart and Margolina, 2018), which is one reason women look at it for skin and hair.
Interest among women centers on fine lines, hair and healing. The regulatory picture changed in 2026: FDA removed injectable GHK-Cu from its 503A Category 2 list in April 2026, and as of the May 14, 2026 list update the injectable route appears in no category, while non-injectable GHK-Cu remains in Category 1 (see the status section below). Correction, September 2026: an earlier version of this paragraph described women using GHK-Cu at FormBlends; that statement has been removed.
Common Side Effects in Women
The selected topical study and registry entry do not measure injectable GHK-Cu side effects in women. The symptom descriptions below are reports rather than incidence or duration measurements from those sources:
From the FormBlends catalog
GHK-Cu (Copper Peptide)
A copper peptide studied for skin and tissue support · From $179/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View GHK-Cu (Copper Peptide) →Correction, September 2026: a bar chart titled Popular Therapeutic Peptides by Use Case, scored on a Clinical Interest Score, previously appeared here. That score was not drawn from any published source and the chart has been removed. The table below replaces it with the FDA compounding status of GHK-Cu by route.
| Route | FDA 503A bulk-substance status (list updated May 14, 2026) | What that means |
|---|---|---|
| GHK-Cu, non-injectable routes (topical and similar) | Category 1 (nominated substance under evaluation, listed with the note: except for injectable routes of administration) | May be compounded by 503A pharmacies under FDA's interim policy while FDA evaluates it; cosmetic topical products are not affected by this list at all |
| GHK-Cu, injectable routes | Removed from Category 2 in April 2026; now in no category | No interim-policy basis for a 503A pharmacy to compound injectable GHK-Cu; FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 |
| GHK-Cu, any route | Not an FDA-approved drug | No FDA-reviewed dosing, safety or efficacy data exist |
- Injection site reactions. Redness, slight swelling, or tenderness where the injection was given. How long these last has not been measured.
- Nausea. The selected sources do not establish its frequency, duration, relationship to food or timing after injectable GHK-Cu.
- Skin flushing. The selected sources do not measure how often it occurs or how quickly it resolves after injectable GHK-Cu.
- Lightheadedness. The selected sources do not quantify this symptom or establish a post-injection pattern.
- Headache. The selected sources do not establish severity or a first-week pattern after injectable GHK-Cu.
Report any side effect to a licensed clinician. Because injectable GHK-Cu has no FDA-reviewed dosing or safety data, there is no established protocol to adjust, and a clinician cannot interpret a symptom without knowing the product and its source.
Hormonal Considerations for Women
A common question is whether GHK-Cu affects hormones. No published study has examined GHK-Cu's effect on estrogen, progesterone or other female hormones in either direction, so the honest answer is that nobody knows. Correction, September 2026: an earlier version reported menstrual changes in some women during the first month; that was anecdotal and has been removed.
If you're on hormone replacement therapy, birth control, or fertility treatments, tell your prescribing clinician about any peptide product you use. No drug-interaction studies exist for GHK-Cu, so there is nothing to consult beyond a clinician's judgment.
Pregnancy and Breastfeeding
GHK-Cu hasn't been studied in pregnant or breastfeeding women. For this reason, we don't recommend GHK-Cu therapy during pregnancy or while nursing. If you become pregnant while on a peptide protocol, contact your provider immediately to discuss next steps.
Serious Side-Effect Reports
The selected studies do not establish how frequently serious side effects occur after injectable GHK-Cu. But women should be aware of the following and seek medical attention if they occur:
- Signs of an allergic reaction (hives, difficulty breathing, swelling of the face or throat)
- Persistent pain, swelling, or warmth at the injection site that worsens over time
- Unusual bruising or bleeding
- Severe headache or vision changes
Seek medical care for any of the above regardless of where the product came from, and bring the product with you so the clinician knows what was used.
How to Minimize Side Effects
A few practical steps can help reduce the likelihood and severity of side effects:
- Use only products with a clear source; for topical products, follow the manufacturer's directions
- Patch-test a new topical product on a small area before wider use
- Stay hydrated, especially on injection days
- Tell your clinician about every peptide product you use, including topical ones
- Report any new symptoms to your care team right away
GHK-Cu regulatory status as of September 2026: topical vs injectable
GHK-Cu is not an FDA-approved drug for any use. Whether a pharmacy can compound it depends on FDA's 503A bulk drug substances list, and that list changed in 2026. On April 15, 2026 FDA announced the removal of 12 peptides from Category 2, including GHK-Cu for injectable routes only, along with BPC-157, TB-500, KPV, Epitalon, Semax and others (law-firm summary, Frier Levitt, April 16, 2026). FDA's own list, updated May 14, 2026, then explains the sequence: GHK-Cu (except for injectable routes of administration) was removed from Category 1 on April 22, 2026 because its nominators withdrew; on May 5, 2026 one nominator clarified that it meant to withdraw only the injectable route, so non-injectable GHK-Cu was added back to Category 1. The same document states that FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 regarding GHK-Cu. The Federal Register notice of April 16, 2026 set the committee's July 23 and 24, 2026 meeting for other peptides (BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, Epitalon); GHK-Cu was not on that agenda.
The practical result for women considering GHK-Cu: topical cosmetic products are unaffected; a 503A pharmacy may compound non-injectable GHK-Cu under FDA's interim policy while evaluation continues; and injectable GHK-Cu currently has no category and therefore no interim-policy basis for compounding. FormBlends does not provide dosing guidance for injectable GHK-Cu.
Sources: FDA, 503A bulk drug substances categories (PDF, updated May 14, 2026); Frier Levitt, April 16, 2026; Federal Register, April 16, 2026 (Doc. 2026-07361).
What the published literature actually contains
The most cited review, Pickart and Margolina's 2018 paper in the International Journal of Molecular Sciences, reports that plasma GHK is about 200 ng/mL at age 20 and falls to about 80 ng/mL by age 60, and that GHK-Cu has been widely used in anti-aging and cosmetic products for decades without adverse effects. Every human study it cites is topical and runs 8 to 12 weeks. It contains no injectable human data, no adverse-event tables and no incidence figures. That review is one source, not a census of all human research. Its topical findings do not establish injectable side-effect rates in women.
Two further cautions follow from the chemistry rather than from trials. GHK-Cu carries copper, so anyone with a copper-handling disorder such as Wilson disease should not use it without a clinician's advice; no study has quantified copper exposure from injected GHK-Cu. And there are no data in pregnancy or breastfeeding, so the only defensible position is to avoid it in both.
Source: Pickart L, Margolina A. Int J Mol Sci 2018 (PMC).
Frequently Asked Questions
Does GHK-Cu cause weight gain in women?
No published study has examined GHK-Cu and body weight in either direction, so there is no evidence it causes weight gain and none that it improves body composition. Correction, September 2026: an earlier version of this answer referred to research on body composition; no such research could be found and the statement has been removed.
Can GHK-Cu affect my menstrual cycle?
No study has looked at GHK-Cu and the menstrual cycle, so there is no evidence either way. If you notice a significant change in your cycle while using any peptide product, tell a clinician and mention the product.
Is GHK-Cu safe for women over 50?
Safety has not been established for injectable GHK-Cu at any age, because no human trial exists. Plasma GHK does decline with age, from about 200 ng/mL at 20 to about 80 ng/mL at 60 (Pickart and Margolina, 2018), which is why interest is high in this group. Topical cosmetic use has a long record without reported adverse effects in the published cosmetic studies. Correction, September 2026: a statement that women over 50 are the most common users was unsourced and has been removed.
Can I use GHK-Cu with my current skincare routine?
Topical GHK-Cu generally pairs well with most skincare products. Dermatologists advise not applying it at the same time as strong acids or high-strength vitamin C, and note irritation or redness at higher concentrations, tingling in reactive skin, and breakouts in acne-prone skin (Westlake Dermatology, February 13, 2026). No specific spacing interval has been studied.
How quickly do side effects go away?
There are no measured data on how long GHK-Cu side effects last; user reports describe effects that settle within hours to days, and injection-site reactions are described as short-lived, but no study has timed them. If any side effect persists or worsens, contact a licensed clinician.
Can a compounding pharmacy legally make injectable GHK-Cu in 2026?
Not under FDA's interim policy as of September 5, 2026. FDA removed injectable GHK-Cu from its 503A Category 2 list in April 2026, and the list updated May 14, 2026 places the injectable route in no category, while non-injectable GHK-Cu remains in Category 1. FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027. Topical cosmetic products are not governed by this list.
Has GHK-Cu been tested in a clinical trial in women?
Only topically. The human studies summarized by Pickart and Margolina (2018) are cosmetic trials of 8 to 12 weeks, and that review reports decades of topical use without adverse effects. There is no published randomized trial of injectable GHK-Cu in women or men, no adverse-event table and no incidence data, so any side-effect percentage for injections is anecdotal.
What side effects does topical GHK-Cu cause?
Dermatologists describe irritation or redness at higher concentrations, tingling in reactive skin, and breakouts in acne-prone skin, and advise against applying it at the same time as strong acids or high-strength vitamin C (Westlake Dermatology, February 13, 2026). No percentages have been published. Patch-test a new product on a small area first and stop if irritation develops.
Sources
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (GHK-Cu status by route; PCAC consultation before end of February 2027). https://www.fda.gov/media/94155/download
- Frier Levitt. FDA peptides do-not-compound list update 2026 (summary of FDA's April 15, 2026 notice removing 12 peptides from Category 2), April 16, 2026. https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
- Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments, Doc. 2026-07361, April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- Westlake Dermatology (Jennifer Gordon, MD). GHK-Cu copper peptides for skin care, February 13, 2026. https://www.westlakedermatology.com/trends/ghk-cu-copper-peptides-for-skin-care/
Ready when you are
GHK-Cu (Copper Peptide)
A copper peptide studied for skin and tissue support · From $179/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View GHK-Cu (Copper Peptide) →